Sidelg

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sidelg

Quick Facts: Sidelg (Orlistat)

Property Description
Active ingredient Orlistat (INN)
Form Hard capsule
Pharmacological class Peripherally acting anti-obesity agent
General purpose Aid in weight management
Origin Synthetic compound

Sidelg: Identity and Pharmacological Classification

Sidelg is a medication containing the active substance Orlistat, which is broadly classified as a peripherally acting anti-obesity agent. This classification means the drug's therapeutic effect is localized to the gastrointestinal tract. The core ingredient, Orlistat, is a synthetic compound derived from lipstatin, and the final product is a single-ingredient product available as an orally administered hard capsule.

Composition and Mode of Action

The mechanism of Sidelg is rooted in its ability to act as a potent and reversible inhibitor of lipase enzymes, chiefly pancreatic lipase. Orlistat achieves this by forming a covalent bond with the active site of these enzymes, thus preventing them from hydrolyzing dietary fat. This action is non-systemic, meaning it works by blocking fat digestion within the gut without requiring significant absorption into the bloodstream. The principle of action—blocking fat absorption locally—is utilized for its role in reducing the caloric impact of dietary fat intake.

General Purpose in Weight Management

The general purpose of Sidelg is to serve as an aid in weight management by reducing the assimilation of dietary fat. By inactivating the lipases, Sidelg prevents the hydrolysis of large dietary triglycerides into absorbable free fatty acids. This action, which limits fat uptake, contributes to the creation of the necessary energy deficit foundational to managing overweight and obesity. The medication is typically considered as an adjunct therapy, used alongside lifestyle modifications, for patients seeking sustained weight control.

Regulatory References

  1. Orlistat - StatPearls - NCBI Bookshelf - NIH
  2. Orlistat: MedlinePlus Drug Information

What side effects are possible with Sidelg?

Possible Side Effects and Safety Information

The safety profile of Sidelg is characterized by both commonly reported adverse reactions and several warnings regarding serious, clinically significant events, as documented in official regulatory labeling.

Common Adverse Reactions

The most frequently reported adverse reactions (ge 20% incidence in trials) generally involve the gastrointestinal and nervous systems. These may include headache, flushing, and dyspepsia (indigestion). Other common events include nasal congestion, back pain, and transient abnormal vision (often a mild color tinge or blurred vision).

System-Organ Class Common Adverse Reactions (Incidence ge 2%)
Nervous System Headache, Dizziness
Vascular Flushing
Gastrointestinal Dyspepsia, Nausea
Ocular Abnormal Vision (Mild and transient)

Serious Warnings and Precautions

Official labeling contains specific warnings concerning serious or potentially life-threatening conditions that have been reported in association with the drug's use. These include:

  • Cardiovascular Risk: Sidelg is contraindicated in patients using nitric oxide donors (such as organic nitrates or nitrites) due to the risk of potentiating severe hypotension. Caution is advised for patients with certain underlying cardiovascular conditions.
  • Ocular Events: Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of sudden vision decrease or loss, has been reported post-marketing. Patients should seek immediate medical attention if a sudden visual disturbance occurs.
  • Hearing Loss: Sudden decrease or loss of hearing has been reported. Patients experiencing this should seek prompt medical care.
  • Priapism: Prolonged erection lasting more than four hours (priapism) is a rare but serious adverse event, requiring immediate medical attention.
  • Drug Interactions: The concomitant use of Sidelg with certain medications, such as some alpha-blockers or strong CYP3A4 inhibitors (e.g., ritonavir), requires caution and potential dose adjustment due to increased risk of hypotension or increased Sidelg exposure.

Contraindications and Restrictions

Sidelg is formally contraindicated in patients with a known history of hypersensitivity to the drug or any component, and in those taking any form of organic nitrates or guanylate cyclase stimulators (like riociguat).

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Sidelg (Orlistat) overdose is defined by the drug's peripheral, non-systemic action. Consequently, post-marketing reports of overdose frequently describe patients as being asymptomatic or experiencing adverse events that are similar to those reported with the recommended dose.

Feature Official Regulatory Statements
Documented Manifestations Primary effects are exaggerated gastrointestinal symptoms such as oily spotting, fecal urgency, fatty or oily stools, and increased defecation.
Systemic Effects Systemic manifestations are officially stated as likely to be rapidly reversible due to minimal absorption.
Antidote Availability No specific antidote is known or available for Sidelg overdose.
Monitoring Requirement If a significant overdose is suspected, the patient should be observed for at least 24 hours under medical supervision.

Emergency Action Required

Government health authorities mandate specific actions for managing an overdose situation. Individuals must seek medical attention right away if they have taken more than the recommended dose, or immediately call emergency services if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The standard management procedure consists of supportive care in a monitored setting, aligning with the absence of a specific antidote.

Therapeutic Uses of Sidelg

What Sidelg Treats: Main Uses and Benefits

Sidelg is applied in addressing conditions related to weight management and the management of cardiometabolic risk factors, offering supportive assistance to patients with persistent weight issues.

Sidelg is commonly used for managing obesity and overweight status in situations where patients experience heightened physiological strain associated with excess weight. It helps address symptom clusters that may create noticeable physiological strain, such as symptoms related to systemic imbalance, including those linked to lipid, glucose, and blood pressure fluctuations. The medication is considered relevant when supportive symptom management is appropriate, particularly for the long-term stabilization of a lower body weight. This approach may assist with maintaining functional stability related to managing persistent excess weight.


Quick Fact: Relief for Cardiometabolic Risk Factors

Domain Benefit
Conditions Obesity, Overweight status with co-morbidities (e.g., hypertension, diabetes).
Symptom Cluster Symptoms related to systemic imbalance, particularly those linked to lipid and blood pressure issues.
Therapeutic Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Sidelg may play a role in managing the overall systemic burden of cardiometabolic risk, and contributes to easing the overall symptom load for patients.

Regulatory References

  1. NIH StatPearls overview on Orlistat

Eligibility and Restrictions for Use

Who Can and Cannot Use Sidelg?

The eligibility for Sidelg (Orlistat) is strictly defined by regulatory criteria that establish both appropriate populations and absolute prohibitions. Official labeling defines use according to age, body mass index (BMI), and specific health conditions.


Absolute Contraindications

Sidelg is explicitly contraindicated and must not be used by individuals with the following conditions or states:

  • Chronic Malabsorption Syndrome or Cholestasis.
  • Pregnancy or Lactation (Breastfeeding).
  • Known Hypersensitivity to the active substance or any component.
  • Concomitant treatment with Ciclosporin (Cyclosporine).

Age-Group Eligibility

Eligibility for use is formally established based on age and body mass index (BMI) thresholds:

Age Group Prescription (120 mg) Status OTC (60 mg) Status
Children (< 12 yrs) Not established Not established
Adolescents ( ge 12 yrs) Eligible with BMI criteria Not established (< 18 yrs)
Adults ( ge 18 yrs) Eligible with BMI criteria Eligible with BMI ge 28 kg/m^2

Use Restrictions

Use requires caution or monitoring for certain populations as specified in the label:

  • Patients with Renal Impairment or a history of oxalate nephrolithiasis require close monitoring of renal function.
  • Patients with Diabetes or Hypothyroidism require close monitoring of their co-administered medications.
  • The medicine is not recommended for patients with eating disorders.

What should I know about interactions with other medicines?

Official Drug-Drug and Substance Interactions

Sidelg's interaction profile is structurally defined by a pharmacokinetic absorption impairment effect on co-administered lipophilic substances. This regulatory classification leads to documented restrictions and mandatory time separation rules for specific medicinal products, as detailed in official government labeling.

Contraindicated and High-Risk Combinations

Interactions officially classified as high-risk include co-administration with Cyclosporine and Vitamin K Antagonists (e.g., Warfarin). Concurrent use with Cyclosporine is often contraindicated because of the risk of decreased plasma levels and reduced efficacy. The interaction with Vitamin K Antagonists is pharmacodynamic, potentially enhancing the anticoagulant effect due to impaired Vitamin K absorption.

Mandatory Administration Timing Rules

Administration timing is a key regulatory constraint to mitigate absorption interference with certain agents:

  • Levothyroxine: Requires separation by at least 4 hours from Sidelg.
  • Cyclosporine: Must be separated by at least 3 hours.
  • Fat-Soluble Vitamins (A, D, E, K) and Beta-Carotene: Must be taken at least 2 hours apart.

Other lipophilic agents, including certain Antiretroviral and Antiepileptic medicines, have documented reduced systemic exposure. The possibility of gastrointestinal adverse reactions is also noted to increase with high dietary fat content in meals.

Mechanism of Action

Targeted Inhibition of Digestive Enzymes

Sidelg (Orlistat) operates by forming a stable, covalent bond exclusively with the active site of key digestive enzymes, chiefly pancreatic lipase and, to a lesser extent, gastric lipase. This interaction is strictly non-systemic, occurring only within the gastrointestinal lumen, which prevents the enzymes from performing their natural function: the breakdown of large dietary triglycerides into absorbable free fatty acids.

⬇️ Interruption of the Fat Hydrolysis Cascade

By inactivating these lipases, the drug directly interrupts the fat hydrolysis cascade, which is the necessary physiological process for nutrient assimilation. The undigested fat molecules are too large to pass through the intestinal wall, leading to their excretion and resulting in a quantifiable reduction in absorbed calories. This mechanism results in an energy deficit at the systemic level, which is the direct consequence of the limitation of nutrient availability.

️ Mechanism Limitations and Constraints

This peripheral mechanism is inherently constrained, as its action is entirely dependent on the presence of dietary fat (the substrate) in the meal. Furthermore, Sidelg achieves only a partial blockade of fat absorption, typically limiting uptake by approximately 30%. Since the body continuously secretes new, unaffected lipase, the enzymatic blockade is sustained only while the drug is present in the lumen, and the effect is reversed by endogenous enzyme turnover.

Dosage and Administration Information

How Sidelg is Used: Administration Guidelines

Sidelg (Orlistat) is administered via the oral route as a hard capsule, based on prescribing information. The medication is dosed three times daily, and its administration is fundamentally tied to meal consumption.

Standard Dosing and Frequency

The standard adult prescription regimen is one 120 mg capsule taken three times daily (TID). A lower strength, one 60 mg capsule three times daily, is also available for non-prescription use. Doses exceeding 360 mg per day are not recommended, as they do not provide additional therapeutic benefit. For adolescents aged 12 years and older, the dose is consistent with the adult prescription regimen, requiring one 120 mg capsule three times daily. No dosage adjustment is required for older adults or those with renal or hepatic impairment.


Administration Timing and Procedural Conditions

Each dose of Sidelg must be taken in direct relation to a meal that contains fat, ensuring that the capsule is swallowed either immediately before, during, or up to one hour after the main meal. If a meal is missed or contains no fat, the corresponding Sidelg dose should be omitted. Because the medicine affects the assimilation of dietary fat, an essential procedural step is the timing of vitamin supplementation; a multivitamin containing fat-soluble vitamins must be taken at a different time, specifically at least two hours before or after the Sidelg dose.

Treatment is intended for long-term use alongside a reduced-calorie, low-fat diet. However, guidelines stipulate that treatment should be discontinued if a patient has not achieved a minimum of 5% weight loss from their baseline within 12 weeks of continuous therapy.

Recent Clinical Evidence

Research evidence / Overview of studies for Sidelg


Evidence for Use in Weight Management in Adults

Research exploring Sidelg for weight management has primarily relied on Randomized Controlled Trials (RCTs). These studies examined outcomes in adults with obesity or overweight (and related risk factors) who were receiving Sidelg as an adjunct to a monitored diet and lifestyle program, against those receiving an inactive placebo. The research monitored outcomes related to body weight and Body Mass Index (BMI) over defined periods.

Studies reported patterns of mean body weight measurements observed in the Sidelg group compared to the placebo group over periods often lasting one year. However, certain limitations in the research should be noted. The differences in weight measurements reported are generally characterized by the researchers as being small in magnitude, and high rates of study discontinuation were documented in many trials.


Evidence for Changes in Cardiometabolic Risk Factors

Research explored Sidelg's use in research contexts focused on changes in specific health markers, primarily in long-term Randomized Controlled Trials. Research examined outcomes related to systemic imbalance, focusing on markers like Serum Cholesterol and monitoring the incidence rate of developing Type 2 Diabetes in high-risk populations.

A major multi-year trial reported patterns showing that the incidence rate of Type 2 Diabetes was measured as lower in high-risk participants receiving Sidelg compared to the placebo group. Research has not fully established whether the measured changes in these markers are only related to the observed weight changes or if other physiological factors were also observed. Furthermore, there is limited information for long-term outcomes regarding the drug’s impact on major cardiovascular events.


Understanding Research Gaps and Uncertainty

Research has explored many aspects of Sidelg, yet evidence highlights what is known — and what is still uncertain. A key limitation is that sample sizes were modest in some studies and evidence quality varies across studies when looking at specific subgroups. Additionally, data for certain groups remain insufficient, particularly older adults or patients with specific combinations of comorbidities. As mentioned, long-term effects are not fully established beyond the four-year mark observed in some studies.

Key Studies & References

  1. Orlistat: An anti-obesity drug for the prevention of type 2 diabetes in obese patients with impaired glucose tolerance
  2. Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Sidelg (FAQ)

Q: What are the most common side effects of Sidelg?

A: According to official regulatory documents, the most frequently reported side effects are related to the gastrointestinal system due to how the medicine works. These can include a change in bowel habits, such as oily spotting, fatty/oily stools, fecal urgency, and flatulence with discharge. Headache is also reported as a very common adverse event.

Q: Is it true that Sidelg can cause stomach upset?

A: Yes, Sidelg commonly causes changes in the digestive system. The official product information reports that gastrointestinal effects, such as abdominal pain, nausea, and dyspepsia (indigestion), are commonly experienced. These occur because the medicine prevents some dietary fat from being absorbed, causing it to pass through the digestive tract.

Q: What happens if I miss a dose of Sidelg?

A: If a main meal is missed, or if the meal contains no fat, regulatory guidance suggests the corresponding dose should be omitted (skipped). The medicine only works when taken with a main meal that contains fat.

Q: Is Sidelg safe for older adults (seniors)?

A: The official product information indicates that no specific dose adjustment is required for older adults. However, regulatory reviews have noted that clinical studies included limited numbers of patients over 65, and data for this specific age group is sometimes noted as insufficient in research summaries.

Q: Can women take Sidelg, or is it only for men?

A: Sidelg is indicated for both women and men who meet the established body mass index (BMI) criteria. However, the medicine is explicitly contraindicated (not recommended for use) during pregnancy and breastfeeding (lactation) due to potential risks.

Q: How is Sidelg different from similar medications with a different name?

A: Sidelg (orlistat) is classified as a lipase inhibitor. This means it works locally in the gastrointestinal tract to block the enzymes that break down dietary fat. This action is non-systemic, differing from other weight management drugs that act on the brain (centrally acting) to affect appetite.

Q: Will Sidelg show up on a standard drug test?

A: Sidelg is designed to be minimally absorbed into the bloodstream and works locally in the gut. Due to its non-systemic mechanism, intact Sidelg in the blood plasma is typically measured near the limits of detection.

Q: What happens if I accidentally take two doses of Sidelg too close together?

A: Official clinical trials administering doses exceeding the recommended daily maximum did not report clinically significant adverse findings. Post-marketing reports of acute overdose generally indicated similar adverse events to the recommended dose.

Q: What is the maximum duration someone usually takes Sidelg?

A: Sidelg is intended for long-term use as an aid to weight management alongside a controlled diet. Official guidelines state that therapy should be discontinued if a minimum of 5% weight loss from the baseline has not been achieved within 12 weeks of continuous therapy.

Q: Does Sidelg interact with anti-depressant medications?

A: The official product label states that Sidelg can reduce the systemic exposure of certain other lipophilic (fat-soluble) medications. This can include some antidepressants, as the medicine's action of fat malabsorption can interfere with the uptake of fat-soluble drugs.

Q: Can Sidelg be taken on an empty stomach?

A: The official product label states that the dose is intended to be taken with each main meal that contains fat, or up to one hour after. The medicine is not typically taken on an empty stomach because it works by acting on the dietary fat consumed.

Q: Can Sidelg be crushed or split in half?

A: Sidelg is supplied as a hard capsule that is intended to be swallowed whole. Regulatory labeling does not contain instructions or data supporting altering the form of the capsule by crushing, splitting, or opening it prior to ingestion.

Q: Can taking Sidelg affect cholesterol levels?

A: Studies summarized in official sources have shown that Sidelg treatment can result in modest improvements in certain health markers. These benefits have been observed in areas such as total cholesterol and low-density lipoprotein (LDL) levels.

Q: How quickly does Sidelg start to work after you take it?

A: Sidelg starts working immediately in the gastrointestinal tract by inhibiting the lipase enzymes that break down fat during the meal. However, the primary clinical outcome that the drug is prescribed for (weight change) is typically assessed after 12 weeks of continuous therapy.

Q: Is there a generic version of Sidelg available?

A: Yes, the active ingredient in Sidelg, known as orlistat, is available in generic formulations, in addition to the brand-name products, according to the FDA’s official drug listings.

Q: How common are serious side effects with Sidelg?

A: The incidence rate for most rare or serious side effects (such as severe liver injury or sudden vision loss) is not precisely quantified in regulatory documents. They are often reported via post-marketing surveillance, which is distinct from the high incidence rate reported for common GI-related side effects.

Q: Is it true that Sidelg works differently in women than in men?

A: Clinical trials reviewed by regulatory bodies found no statistically significant differences in the mean weight loss outcomes achieved by male and female participants.

Q: Can Sidelg be used 'as needed' or does it have to be taken regularly?

A: Official labeling suggests taking Sidelg with each main meal that contains fat. While a dose is skipped if a meal is missed or contains no fat, it is generally intended to be used as a regular adjunct to diet, not on an 'as needed' basis for sporadic use.

Q: Is it normal for the effect of Sidelg to decrease over time?

A: Official data indicates that the common gastrointestinal side effects tend to decrease with continued treatment. Furthermore, clinical trials demonstrated that Sidelg remained effective for the maintenance of lost weight over long periods of therapy.

Q: Will taking Sidelg cause weight gain or loss?

A: Sidelg is indicated as an aid for weight loss and maintenance. However, the official documentation mentions both the therapeutic goal (weight loss) and post-marketing reports of weight gain as an adverse event.

Q: Is a metallic taste in the mouth a known side effect of Sidelg?

A: A metallic taste is not listed among the common or severe side effects in primary regulatory documents. However, rare post-marketing reports have noted a general change in the sense of taste.

Q: Are there any studies showing Sidelg's effectiveness in younger adults?

A: Sidelg is FDA-approved for use in adolescents 12 years of age and older who meet specific BMI criteria. Clinical trials conducted in adolescents showed a small but significant decrease in body mass index (BMI) compared to placebo.

Q: Is it okay to drive or operate machinery while taking Sidelg?

A: According to the official product information reviewed by European regulatory agencies, Sidelg has no known influence on the ability to drive or operate heavy machinery.

How should Sidelg be stored and disposed of?

How to Store and Dispose of Sidelg (Orlistat)

The official storage requirements for Sidelg hard capsules are specified by regulatory labeling to maintain product stability and integrity.


Storage Conditions

Sidelg must be stored at controlled room temperature, generally not exceeding 25 C (77 F). The product must be protected from both light and moisture and should be kept in its original container, which must remain tightly closed. It is explicitly stated that Sidelg should not be frozen or stored in a refrigerator.

Furthermore, the medicine must be strictly kept out of the sight and reach of children.


Disposal Instructions

To dispose of expired or unused Sidelg, patients must follow local requirements for pharmaceutical waste handling. Official guidance instructs that Sidelg must not be disposed of via wastewater (flushing) or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sidelg found in:

A-Z Index: